Budenofalk (budesonide gastro-resistant) / Dr Falk - LARVOL DELTA

Relative Bioavailability Study of HR19042 in Healthy Subjects (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Autoimmune Hepatitis • Glomerulonephritis • Hepatology • IgA Nephropathy • Immunology • Inflammation • Renal Disease

ONSET OF NONSPECIFIC ULCERATIVE COLITIS POST COVID-19 (CASE STUDY). (PubMed, Wiad Lek) - "According to the family doctor's prescription, she took Azithromycin 500 mg a day per os for 6 days, and then Ceftriaxone 1.0 g twice a day i.m. for another 6 days. The patient started treatment with Salofalk first at a dose of 2 mg and then 4 mg per day. Due to the insufficient clinical effect, the patient was additionally prescribed Budenofalk in a daily dose of 9 mg with a positive clinical effect."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Novel Coronavirus Disease • Ulcerative Colitis

An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression. (PubMed, Sci Rep) - "We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of patients with IgA Nephropathy...Budesonide was well-tolerated, and treatment emergent adverse events were mostly mild in severity and reversible. Budesonide was effective in the treatment of patients with IgAN at high-risk of progression in terms of reducing proteinuria and preserving renal function over 36 months of therapy."

Journal • Glomerulonephritis • IgA Nephropathy • Renal Disease

An Open-Label Trial Evaluating the Safety and Efficacy of Budesonide in Patients with IgA Nephropathy at High Risk of Progression (KIDNEY WEEK 2023) - "Budesonide (Budenofalk) was effective in the treatment of patients with IgAN at high-risk of progression in terms of reducing proteinuria, hematuria and preserving renal function over 36 months of therapy."

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy and safety of medical therapies in microscopic colitis: a systematic review and network meta-analysis. (PubMed, Therap Adv Gastroenterol) - "Entocort 9 mg/day ranked first among the treatment options in inducing remission and Budenofalk 6 mg/3 mg alternate day dosing for maintaining remission in the treatment of MC. Moving forward, mechanistic studies exploring the differences between Entocort and Budenofalk would be valuable whilst future RCT studies are needed in non-corticosteroidal maintenance, particularly looking into immunomodulators, biologics and probiotics."

Journal • Retrospective data • Review • Gastroenterology • Gastrointestinal Disorder • Immune Modulation • Immunology

Matrix tablets based on a novel poly (magnesium acrylate) hydrogel for the treatment of inflammatory bowel diseases. (PubMed, Int J Pharm) - "When the dissolution medium was changed sequentially throughout the trial, 75% of the budesonide dose was released in a sustained manner between 4 and 20 hours of testing from PAMgA tablets, showing a more controlled budesonide release than Entocort® and Budenofalk® (commercially available sustained release formulations of budesonide). In conclusion, PAMgA polymer allows controlling the release of highly lipophilic drugs as budesonide, being an useful excipient for the development of sustained release matrix tablets."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

"Budesonide MMX - is it Budenofalk granules or Cortiment tablets? Sorry, only such budesonide preparations are available to us" (@al1506UA)

Exclusive Enteral Nutrition in Patients With Ileoceacal Crohn's Disease (clinicaltrials.gov) - P3; N=256; Recruiting; Sponsor: Duzce University

Clinical • New P3 trial • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

Medicinal products with controlled drug release for local therapy of inflammatory bowel diseases from perspective of pharmaceutical technology. (PubMed, Ceska Slov Farm) - "Specifically, it focuses on pharmaceutical drugs containing 5-aminosalicylic acid (Asacol®, Pentasa®, Salofalk®) and budesonide (Budenofalk®, Cortiment®, Entocort®). As a part of this paper, basic recommendations and practical information that can be used in clinical practice are also given."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison. (PubMed, Medicine (Baltimore)) - "The median reduction in hematuria at 24-month was 72% (IQR: -90%; -45%) in the budesonide group and 73% (IQR: -85%; 18%) in the corticosteroid group, respectively (P = .22, for between group difference). Treatment with budesonide was well tolerated with minimal side effects.Budesonide (Budenofalk) was effective in the treatment of patients with IgAN at high-risk of progression in terms of reducing proteinuria, hematuria and preserving renal function over 24 months of therapy."

Journal • Retrospective data • Renal Disease

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. (PubMed) - "Treatment extension with low-dose budesonide beyond 1year may be beneficial given the high relapse rate after budesonide discontinuation."

Journal • Biosimilar • Hematological Malignancies • Inflammatory Bowel Disease • Oncology